RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia

Overview

Hypothesis. Combined treatment with novasure and mirena IUS confers benefit over Novasure alone in the treatment of menorrhagia

Full Title of Study: “RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia. A Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 2014

Detailed Description

Endometrial ablation is a commonly used treatment option for women with heavy periods. It is recommended as an initial treatment. It aims at destroying the lining of the womb to reduce heavy menstrual loss. A hormone releasing device in the womb (MIRENA®)is another commonly used treatment for women with heavy menstrual bleeding and has added benefit of reducing cyclical pain. There is an increase in the number of women presenting to gynaecology clinic with persistence of pain or cyclical pain with absent or light bleeding after second generation endometrial ablation (Novasure). This may be due to the pockets of active lining of the womb that remains after ablation or possible adhesions created by the treatment. Most women require surgical removal of the womb (hysterectomy) because of pain or a further surgical procedure to divide these adhesions in an attempt to relieve pain and drain any collections in the womb. We aim to determine if the combined use of MIRENA® and NOVASURE® (which is the second generation endometrial ablation technique used in our unit) will help in reducing the number of women presenting with cyclical pain and requiring further intervention or surgery. The aim of the current study is to compare between women receiving only NOVASURE treatment and women receiving combined NOVASURE and MIRENA treatment for heavy menstrual bleeding. The primary and secondary outcomes will be assessed at 6 and 12 months by a patient questionnaire. The primary outcome is improvement in quality of life The secondary outcomes include – Lowering of surgical intervention – Reduction in pain – Reduction in amount of bleeding This will be a pilot study to determine if the theory is correct and then a larger powered study can be undertaken

Interventions

  • Procedure: novasure mirena IUS combined
    • novasure mirena IUS combined

Arms, Groups and Cohorts

  • Active Comparator: novasure mirena IUS combined
    • novasure mirena IUS combined therapy
  • Active Comparator: novasure alone
    • Sole treatment with Novasure

Clinical Trial Outcome Measures

Primary Measures

  • Quality of life
    • Time Frame: 6 months
    • Patient questionaire to assess periods and pain

Participating in This Clinical Trial

Inclusion Criteria

  • Anybody suitable for novasure ablation Exclusion Criteria:

  • Mirena IUS is indicated as treatment

Gender Eligibility: Female

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Walsall Healthcare NHS Trust
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mr jonathan pepper MD FRCOG, Consultant Gynaecologist – Walsall Healthcare NHS Trust

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.